Brevicidine
Brevicidine is an antimicrobial peptide with selective bactericidal activity against Gram-negative pathogens. Brevicidine disrupts bacterial morphology by binding to lipopolysaccharide (LPS) on the bacterial cell membrane to form pores. Brevicidine causes dissipation of intracellular proton motive force, outer membrane damage, inhibition of ATP biosynthesis and reactive oxygen species accumulation in bacterial cells. As a sensitizer, Brevicidine exerts synergistic activity when combined with a variety of conventional antibiotics.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2676889-05-5
- Formule: C74H106N18O17
- Masse moléculaire:1519.74
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HK-2 | IC50 |
36.5 μM
Compound: Brevicidine
|
Cytotoxicity against human HK-2 cells measured after 24 hrs MTT assay
Cytotoxicity against human HK-2 cells measured after 24 hrs MTT assay
|
[PMID: 38537511] |
Brevicidine (0-2 μM; 20 h) acts as a synergistic sensitizer. When combined with outer membrane-impermeable antibiotics (Erythromycin (HY-B0220),
Azithromycin (HY-17506), Vancomycin (HY-B0671)) against Acinetobacter baumannii strains, it reduces the MIC by up to 128-fold at concentrations as low as 1 μM[1].
Brevicidine (0.125-4 μM; 25 min) disrupts the outer membrane of Acinetobacter baumannii ATCC 17978 in a dose-dependent manner[1].
Brevicidine (1-4 μM; 1 h) inhibits ATP synthesis and induces ROS production in Acinetobacter baumannii, and this effect is enhanced when used in combination with Erythromycin[1].
Brevicidine (1-16 mg/L; 20 h) selectively inhibits Gram-negative pathogenic bacteria with an MIC range of 1-16 mg/L, and shows no activity against Gram-positive pathogenic bacteria[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male)[1]
-
Dosage:5 mg/kg (monotherapy); 5 mg/kg (combined with 5 mg/kg Erythromycin)
-
Administration:i.v.; single dose
-
Result:Reduced the death rate of A. baumannii-infected mice from 80% to 60%; significantly reduced bacterial load in the liver and spleen.
Achieved 100% survival when combined with 5 mg/kg Erythromycin; showed greater reduction in bacterial loads across organs when combined with Erythromycin compared to monotherapy.
Chemical Information
-
CAS No. 2676889-05-5
-
Masse moléculaire 1519.74
-
Formule C74H106N18O17
-
Sequence
4-Methylhexanoyl-{d-Asn}-{d-Tyr}-{d-Trp}-{d-Orn}-{Orn}-Gly-{d-Orn}-Trp-Thr-Ile-Gly-Ser (Lactone: Thr9-Ser12)
-
Sequence Shortening
4-Methylhexanoyl-{d-Asn}-{d-Tyr}-{d-Trp}-{d-Orn}-{Orn}-G-{d-Orn}-WTIGS (Lactone: Thr9-Ser12)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Brevicidine Related Classifications
HY-P10519 Related Classifications
Powered by Bioz